GLP-1 receptor agonist
FDA-approved prescription products for specific diabetes and weight-management uses; Wegovy also has cardiovascular-risk and MASH indications. Product and population matter.
Study: A major trial found 14.9% average weight loss at 68 weeks, versus 2.4% with placebo, in adults without diabetes. Both groups received lifestyle support.12
Community: Secondary community reports focus on appetite and weight.7
Wegovy has accelerated approval for adults with specified liver fibrosis.4
31 residues · N → C16
H–Aib–E–G–T–F–T–S–D–V–S–S–Y–L–E–G–Q–A–A–K*–E–F–I–A–W–L–V–R–G–R–GAib replaces alanine at sequence position 2. K* at sequence position 20 carries semaglutide’s acylated side chain. Positions are counted within this 31-residue sequence.
Chemical properties refer to semaglutide, not an unspecified salt or retail powder.
Illustrative model using reported human data.
Five half-lives in this simplified model. This is not a prediction of when effects stop.
Label elimination estimate. Oral and injectable products have different absorption and are not mg-for-mg substitutes.
Population: Patients with overweight or obesity
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
Illustrative scenario using an unverified reference estimate.
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Population: Not established by the reference estimate
Source’s stated attribution: FDA Ozempic Label
Source’s reported peak time: 1 day. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects. The source attributes the oral-tab estimate to an injectable Ozempic label; that attribution does not verify oral absorption timing.
Illustrative scenario using an unverified reference estimate.
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Population: Not established by the reference estimate
Source’s stated attribution: FDA Ozempic Label
Source’s reported peak time: 1 hr. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
STEP 1 mean weight change was −14.9% with semaglutide versus −2.4% with placebo.1
Glucose 1–4 weeks; weight changes accumulate over 2–6+ months. Source percentage ranges are not individual forecasts.18
These are reported timelines, not a prediction of your response.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 2.4 mg target | Once weekly | Weight reduction: STEP 11,961 adults with obesity/overweight without diabetesHuman study | 68 weeks | 1 |
Population 1,961 adults with obesity/overweight without diabetes Context Target followed escalation; all groups received lifestyle intervention. | |||||
| SubQ | 0.25 mg | Weekly x 4 weeks, then increase | Weight Loss InitiationReference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable | |||||
| SubQ | 2.4 mg | Weekly (after 16-week titration) | Weight Loss MaintenanceReference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable | |||||
| SubQ | 0.5-1 mg | Weekly | Diabetes ManagementReference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable | |||||
| SubQ | 0.5-1 mg | Weekly | Cardiovascular ProtectionReference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable | |||||
| SubQ | 0.25-2.4 mg | Weekly (individualized) | Tolerability-BasedReference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable | |||||
| OralOral (empty stomach) | 3 mg | Daily x 30 days | Diabetes Initiation (Rybelsus)Reference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
| OralOral (empty stomach) | 7 mg | Once daily | Standard Diabetes Dose (Rybelsus)Reference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
| OralOral (empty stomach) | 14 mg | Once daily | Maximum Diabetes Dose (Rybelsus)Reference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
| OralOral (empty stomach) | 1.5 mg | Daily x 4 weeks | Weight Loss Initiation (Oral Wegovy)Reference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
| OralOral (empty stomach) | 4 mg | Daily x 4 weeks | Weight Loss Escalation 1 (Oral Wegovy)Reference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
| OralOral (empty stomach) | 9 mg | Daily x 4 weeks | Weight Loss Escalation 2 (Oral Wegovy)Reference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
| OralOral (empty stomach) | 25 mg | Once daily | Weight Loss Maintenance (Oral Wegovy)Reference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
| OralOral (empty stomach) | 3-7 mg | Daily (no adjustment needed) | Renal ImpairmentReference report | Ongoing treatment as prescribed | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Any time of day, with or without food
First thing in morning, 30+ min before food/drink/meds
Gastrointestinal symptoms include nausea, vomiting, diarrhea and constipation.
3Contraindicated with personal/family MTC or MEN2; human tumor risk is unknown.
3Warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.
3Label specifies discontinuation at least 2 months before a planned pregnancy.
3GI symptoms, fatigue, headache, hair loss and altered skin sensations.
MTC/MEN2 contraindication; pancreatitis, gallbladder disease, dehydration/kidney injury, retinopathy, aspiration and pregnancy risks.
Abdominal pain, jaundice, neck swelling, dyspnea/allergy, low urine, vision changes, confusion or fainting.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Hypoglycemia.18
Reference report · Pep-Pedia label: Monitor CombinationHypoglycemia.18
Reference report · Pep-Pedia label: Monitor CombinationIncretin duplication.18
Reference report · Pep-Pedia label: Avoid CombinationGLP-1 duplication.18
Reference report · Pep-Pedia label: Avoid CombinationProduct-specific absorption instructions.18
Reference report · Evidence context: Requires timingIncreased hypoglycemia risk.3
Research contextWegovy coadministration is not recommended.3
Research contextDelayed gastric emptying may affect absorption; monitoring can be needed.3
Research contextStudied as CagriSema, not homemade stack.18
Reference report · Pep-Pedia label: SynergisticEstablished co-treatment.18
Reference report · Pep-Pedia label: CompatibleUntested pairing.18
Reference report · Evidence context: CompatibleNo proven GI protection.18
Reference report · Pep-Pedia label: CompatibleNo matching interactions. Try another name or filter.
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Enter an amount to calculate its volume and device setting.
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Wegovy injectable pens contain solution; no reconstitution.3
Research powder and compounded salts are not the labeled pen formulation.3
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
The source describes a ready-made pen or vial, not a dry-powder mixing protocol.
Pen priming, hold time, refrigeration and in-use expiry vary by branded presentation. The source’s 28-day storage line is not universal.
The source describes oral-tablet handling.
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.18
Product-specific storage; no reconstitution.
Before first use: 2–8°C. After first use: 56 days at 15–30°C or 2–8°C. Do not freeze; protect from heat and light.19
Normally 2–8°C; up to 28 days at 8–30°C in the original carton. Discard after use.19
Normally 2–8°C; before cap removal, up to 28 days at 8–30°C in the original carton. Do not freeze; discard after use.20
Before first use: 2–8°C. After first use: up to 56 days at 15–30°C or 2–8°C. Do not freeze; protect from heat and light.20
20–25°C, dry, in the original closed bottle. These product-specific rules do not establish expiry for a reconstituted research vial.20
Refrigerate before first use, then refrigerate or room temp up to 28 days
Room temperature in original blister pack
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Device units measure volume. Concentration determines the amount in mg.
Documented 1-unit V2 models
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
100 units = 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
mL syringes and calibrated pipettes
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Trial averages do not predict individual weight loss or tolerance.1
4 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams.
A GLP-1 receptor agonist studied in large human trials. Its prescription products have different indications and formulations; dose amounts cannot be transferred between oral, injectable and research products.
Other names: Sema · Ozempic · Wegovy · Rybelsus · Wegovy HD
FDA-approved prescription products for specific diabetes and weight-management uses; Wegovy also has cardiovascular-risk and MASH indications. Product and population matter.
31 amino acids · 4,113.64 Da
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-GlyReference description; checked chemical identity takes precedence when available.18
Glucose-dependent insulin secretion, glucagon suppression, appetite regulation and delayed gastric emptying; oral absorption uses SNAC.18
In 1,961 adults without diabetes, weekly 2.4 mg plus lifestyle support produced 14.9% mean weight loss at 68 weeks, versus 2.4% with placebo plus lifestyle support.
1FDA approved Wegovy HD 7.2 mg injection in March 2026 for weight loss and maintenance in eligible adults. Older 2.4 mg studies remain evidence for that specific regimen, not the entire current product range.
2In adults without diabetes, 72-week weight change was −18.7% with 7.2 mg and −15.6% with 2.4 mg (treatment-policy estimand). Dysaesthesia and GI events were more common with the higher dose.
6May 2026 label: multi-dose pen after first use 56 days at 15–30°C or 2–8°C; single-dose syringe 28 days at 8–30°C. Protect from light; do not freeze. Does not establish research-vial stability.
Approved product label19June 2026 label: capped single-dose pen/syringe 28 days at 8–30°C; FlexTouch multi-dose pen 56 days after first use at 15–30°C or 2–8°C. Tablets 20–25°C in original dry bottle. Injectable has a noncirrhotic MASH F2–F3 indication; oral indications differ.
Approved product label20Weight management. A major trial found 14.9% average weight loss at 68 weeks, versus 2.4% with placebo, in adults without diabetes. Both groups received lifestyle support.12
MASH. Wegovy has accelerated approval for adults with specified liver fibrosis.4
Weight. Appetite, cravings and maintenance; oral/injectable product evidence differs.18
Diabetes / cardiovascular. Glycemic control and cardiovascular outcomes.18
Metabolic. Liver disease, insulin sensitivity, lipids and inflammation research.18
Pep-Pedia discusses appetite control and weight management. Its protocol table is secondary and does not capture every current approved semaglutide formulation.7
A secondary protocol description, not a clinical recommendation or a representative survey. Dose, product identity, other compounds and outcome reporting are not independently verified.
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
AI-prepared summaries. Independent medical editorial review is pending.
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Number of responses to this question: not disclosed.
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source hides 9 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source displays “329 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
Original sources and review status. Open a reference to read its summary.
Randomized 68-week trial: average weight loss was 14.9% with 2.4 mg weekly plus lifestyle support and 2.4% with placebo plus lifestyle support.
In 1,961 adults without diabetes, weekly 2.4 mg plus lifestyle support produced 14.9% mean weight loss at 68 weeks, versus 2.4% with placebo plus lifestyle support.
FDA approved Wegovy HD 7.2 mg injection for weight reduction and maintenance in eligible adults on March 19, 2026.
FDA approved Wegovy HD 7.2 mg injection in March 2026 for weight loss and maintenance in eligible adults. Older 2.4 mg studies remain evidence for that specific regimen, not the entire current product range.
Product-specific prescribing information. Review it for current indications, presentations, contraindications and warnings.
The expanded indication covers adults with MASH and moderate-to-advanced liver fibrosis; it is not an approval for all liver disease.
Identifies semaglutide as a modified 31-residue peptide and records its formula.
72-week phase 3b trial: treatment-policy mean weight change −18.7% with 7.2 mg versus −15.6% with 2.4 mg and −3.9% placebo; dysaesthesia and GI events were more frequent at 7.2 mg.
In adults without diabetes, 72-week weight change was −18.7% with 7.2 mg and −15.6% with 2.4 mg (treatment-policy estimand). Dysaesthesia and GI events were more common with the higher dose.
Additional research · Checked 2026-10-12
Accessed October 12, 2026. Reports commonly discussed protocols; these schedules are unvalidated descriptions, not evidence of safety or efficacy.
Catalog lists research vials including 2, 5, 10, 15, 20 mg. Seller labels only: contents and suppliers are not independently verified or endorsed, and these are not market-frequency estimates.
Pep-Pedia reports: The oral trial is described as producing about 14% versus 2.4% weight loss over 64 weeks in adults without diabetes; approved-product details need a label.
Reported population / model
307 participants
Reported study details
25mg daily · 64 weeks · ~14% weight loss (~33 lb) vs 2.4% placebo
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The cardiovascular trial found a reported 20% relative reduction in major events in people with established cardiovascular disease; absolute risk also matters.
Reported population / model
17,604 participants
Reported study details
2.4mg weekly · 5 years · 20% CV risk reduction
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The source reports 15.2% mean weight loss at 104 weeks with continued treatment in a 304-person study.
Reported population / model
304 participants
Reported study details
2.4mg weekly · 104 weeks · Sustained weight loss
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The adolescent trial reported a 16.1% reduction in BMI over 68 weeks; this is a pediatric obesity population with supervised care.
Reported population / model
201 adolescents
Reported study details
2.4mg weekly · 68 weeks · 16.1% BMI reduction
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Adults in STEP 1 lost an average 14.9% of weight versus 2.4% with placebo alongside lifestyle support.
Reported population / model
1,961 participants
Reported study details
2.4mg weekly · 68 weeks · 14.9% weight loss
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The oral diabetes program evaluated several doses and trials; pooled descriptions should not replace individual trial-specific HbA1c results.
Reported population / model
9,543 participants
Reported study details
3-14mg daily · 26-78 weeks · Oral efficacy
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The injectable diabetes program reported HbA1c reductions around 1.5–1.8 points across studies; effects depend on baseline and comparator.
Reported population / model
Multiple trials
Reported study details
0.5-1mg weekly · Various durations · HbA1c reduction
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Sequence and modifications checked October 12, 2026. Aib replaces alanine at sequence position 2. K* at sequence position 20 carries semaglutide’s acylated side chain. Positions are counted within this 31-residue sequence.
Lists a half-life of 7 days and a peak time of 1 day. Stated attribution: FDA Ozempic Label. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
May 2026 label: multi-dose pen after first use 56 days at 15–30°C or 2–8°C; single-dose syringe 28 days at 8–30°C. Protect from light; do not freeze. Does not establish research-vial stability.
May 2026 label: multi-dose pen after first use 56 days at 15–30°C or 2–8°C; single-dose syringe 28 days at 8–30°C. Protect from light; do not freeze. Does not establish research-vial stability.
Additional primary-source check · Checked 2026-10-12
June 2026 label: capped single-dose pen/syringe 28 days at 8–30°C; FlexTouch multi-dose pen 56 days after first use at 15–30°C or 2–8°C. Tablets 20–25°C in original dry bottle. Injectable has a noncirrhotic MASH F2–F3 indication; oral indications differ.
June 2026 label: capped single-dose pen/syringe 28 days at 8–30°C; FlexTouch multi-dose pen 56 days after first use at 15–30°C or 2–8°C. Tablets 20–25°C in original dry bottle. Injectable has a noncirrhotic MASH F2–F3 indication; oral indications differ.
Additional primary-source check · Checked 2026-10-12